Literature DB >> 17690852

Progressive myoclonic ataxia with intrathecal immune activation in six patients.

D Testa1, E Ambrosoni, S Franceschetti, A Salmaggi, P Soliveri, F Girotti.   

Abstract

In six patients with slowly progressive sporadic cerebellar ataxia and cortical multifocal action myoclonus, cerebrospinal fluid (CSF) IgG index was persistently very high (1.2-6.7) and numerous oligoclonal bands were detected. Progressive cognitive impairment and MRI cerebellar and cerebral atrophy were observed. No serum antibodies were found. Various degenerative, metabolic, inflammatory and systemic diseases were excluded. The cerebellum may be the main target of a degenerative or immune process and releases antigens that, enhancing a compartmentalised (auto)immune response, as suggested by the persistent intrathecal activation, could lead to further cerebellar damage. As the frequency of CSF oligoclonal banding in myoclonic ataxia is unknown, our patients' disease might represent a hitherto unreported entity or a subset of progressive myoclonic ataxia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690852     DOI: 10.1007/s10072-007-0821-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  24 in total

Review 1.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

Review 2.  Immunotherapeutic approaches to Alzheimer's disease.

Authors:  Alon Monsonego; Howard L Weiner
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

3.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

4.  Cortical myoclonus and cerebellar pathology.

Authors:  M A Tijssen; M Thom; D W Ellison; P Wilkins; D Barnes; P D Thompson; P Brown
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

5.  Intrathecal immune activation in three patients with progressive myoclonic ataxia.

Authors:  A Salmaggi; F Carella; C Ciano; S Binelli; P Giovannini; E Palazzini; F Girotti
Journal:  Mov Disord       Date:  1995-03       Impact factor: 10.338

6.  CSF oligoclonal bands, immunoglobulins, and viral antibodies in progressive myoclonus epilepsy.

Authors:  M Iivanainen; P Leinikki; E Taskinen; I C Shekarchi; D Madden; J Sever
Journal:  Arch Neurol       Date:  1981-04

Review 7.  Electrophysiological studies of myoclonus.

Authors:  H Shibasaki
Journal:  Muscle Nerve       Date:  2000-03       Impact factor: 3.217

8.  Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease.

Authors:  L Canafoglia; C Ciano; F Panzica; V Scaioli; C Zucca; P Agazzi; E Visani; G Avanzini; S Franceschetti
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

Review 9.  Molecular mechanisms of axonal damage in inflammatory central nervous system diseases.

Authors:  Harald Neumann
Journal:  Curr Opin Neurol       Date:  2003-06       Impact factor: 5.710

Review 10.  Movement disorders in multiple sclerosis.

Authors:  C Tranchant; K P Bhatia; C D Marsden
Journal:  Mov Disord       Date:  1995-07       Impact factor: 10.338

View more
  1 in total

1.  Progressive myoclonic epilepsies: definitive and still undetermined causes.

Authors:  Silvana Franceschetti; Roberto Michelucci; Laura Canafoglia; Pasquale Striano; Antonio Gambardella; Adriana Magaudda; Paolo Tinuper; Angela La Neve; Edoardo Ferlazzo; Giuseppe Gobbi; Anna Teresa Giallonardo; Giuseppe Capovilla; Elisa Visani; Ferruccio Panzica; Giuliano Avanzini; Carlo Alberto Tassinari; Amedeo Bianchi; Federico Zara
Journal:  Neurology       Date:  2014-01-02       Impact factor: 9.910

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.